文献速递骨软组织肉瘤与黑色素瘤

瘤内注射Sotigalimab联合帕博利珠单抗治疗转移性黑色素瘤的I/II期研究

Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study.
PubMed 文献 · Cancer Discov · 2026-01-01

该I/II期研究评估瘤内注射CD40激动剂Sotigalimab联合帕博利珠单抗在32例未经免疫检查点抑制剂治疗的转移性黑色素瘤患者中的安全性和疗效。结果显示联合治疗耐受良好,推荐II期剂量下客观缓解率为50%,疾病控制率92%,注射瘤灶和非注射瘤灶的ORR分别为67%和50%。多组学分析显示治疗激活了抗原呈递细胞并诱导了全身性免疫应答。

要点

  • 瘤内Sotigalimab联合帕博利珠单抗在未经ICB治疗的转移性黑色素瘤中耐受良好。
  • 推荐II期剂量下ORR为50%,DCR为92%,非注射瘤灶ORR达50%。
  • 疗效与免疫学改变相关,支持进一步随机II期试验评估「原位免疫」策略。

核心结论

  • 瘤内注射Sotigalimab联合帕博利珠单抗安全可耐受,能激活抗原呈递细胞并在注射和非注射瘤灶中引发广泛的固有和适应性免疫应答。

研究设计与样本

  • I/II期研究(NCT02706353),纳入32例未经免疫检查点抑制剂治疗的转移性黑色素瘤患者,评估瘤内Sotigalimab联合帕博利珠单抗的安全性和客观缓解率。

主要发现

  • 推荐II期剂量下客观缓解率为50%,疾病控制率为92%,注射瘤灶ORR为67%,非注射瘤灶ORR为50%。
  • 多组学分析显示Sotigalimab有效激活CD40通路,增加髓系细胞(包括CD11c+DC-LAMP+树突状细胞和巨噬细胞)的浸润和活化。
  • 联合治疗在注射瘤灶中激活固有和适应性免疫,在非注射瘤灶中激活细胞毒性应答。
  • T细胞受体测序显示T细胞克隆性增加,并出现跨肿瘤共享的新扩增克隆。
  • 临床缓解与上述免疫学改变相关,但与抗PD-1单药治疗的基线应答特征无关。

临床怎么用

  • 对于未经ICB治疗的转移性黑色素瘤患者,瘤内Sotigalimab联合帕博利珠单抗可作为潜在治疗策略,通过「原位免疫」增强抗PD-1疗效。

局限性

  • 本研究为I/II期单臂研究,样本量有限,需进一步随机II期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Immune checkpoint blockers (ICB) improve outcomes in metastatic melanoma (MM), but resistance limits benefit. This phase I/II (NCT02706353) study evaluated intratumoral sotigalimab (anti-CD40 agonist) with pembrolizumab in 32 patients with ICB-naïve MM. Primary endpoints were safety and objective response rate (ORR). Sotigalimab was well tolerated. At the recommended phase II dose, the ORR was 50%, and the disease control rate was 92%, with ORRs of 67% in injected and 50% in non-injected tumors. Multiomic analyses of tumor and blood showed that sotigalimab effectively engaged the CD40 pathway, boosting infiltration and activation of myeloid cells, including CD11c+DC-LAMP+ dendritic cells and macrophages. The combination therapy activated innate and adaptive immunity in injected tumors and cytotoxic responses in non-injected tumors. T-cell receptor sequencing showed increased T-cell clonality with expanded new clones shared across tumors. Clinical responses correlated with these immunologic changes but not with baseline features associated with response to anti-PD-1 monotherapy. SIGNIFICANCE: In this study, we provide compelling data that intratumoral sotigalimab combined with pembrolizumab is safe, activates antigen-presenting cells, and elicits broad innate and adaptive immune responses in both injected and non-injected tumors, supporting further randomized phase II trials to evaluate sotigalimab's potential to enhance anti-PD-1 therapy through "in situ" immunization.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Bentebibel SE, McGrail DJ, Kochat V, et al. Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study. Cancer Discov. 2026. PMID: 42013310. doi:10.1158/2159-8290.CD-25-1551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。